Brief: Celyad Presents Update On CYAD-01 Hematological Malignancies Program

Celyad Oncology SA

04/12/2018 07:04

Dec 4 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD PRESENTS UPDATE ON CYAD-01 HEMATOLOGICAL
MALIGNANCIES
CLINICAL PROGRAM AT 60TH ASH ANNUAL MEETING
    * CYAD-01 WITHOUT PRECONDITIONING CHEMOTHERAPY WAS
WELL-TOLERATED
AND DEMONSTRATED ANTI-LEUKEMIC ACTIVITY IN FIVE OUT OF EIGHT
(62%) EVALUABLE PATIENTS
    * SECOND CYCLE OF CYAD-01 DEMONSTRATED ABILITY TO REDUCE
RELEVANT
BONE MARROW BLAST IN R/R AML PATIENT POST-HEMATOLOGICAL RELAPSE
    * PRELIMINARY SAFETY DATA FROM DEPLETHINK PHASE 1 TRIAL,
EVALUATING CYAD-01 WITH PRECONDITIONING CHEMOTHERAPY IN R/R AML
PATIENTS SHOWED ADMINISTRATION IN ONGOING FIRST DOSE COHORT WAS
WELL-TOLERATED WITH NO GRADE 3 OR 4 TREATMENT-RELATED ADVERSE
EVENTS

Source text for Eikon:  ID:nGNX4w0WK 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom:)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))